Mutations in the <it>Plasmodium falciparum cytochrome b </it>gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil

Mutations in the <it>Plasmodium falciparum cytochrome b </it>gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil

<p>Abstract</p> <p>Background</p> <p>Fixed-dose combination antimalarial drugs have played an increasingly important role in the treatment and chemoprophylaxis of falciparum malaria since the worldwide failure of monotherapy with chloroquine. Atovaquone-proguanil is one...

Full description

Bibliographic Details
Main Authors:	Fivelman Quinton L, Burke Martina, Price Nicholas, Laundy Matt, Sutherland Colin J, Pasvol Geoffrey, Klein John L, Chiodini Peter L
Format:	Article
Language:	English
Published:	BMC 2008-11-01
Series:	Malaria Journal
Online Access:	http://www.malariajournal.com/content/7/1/240

Similar Items

Detection of atovaquone-proguanil resistance conferring mutations in <it>Plasmodium falciparum </it>cytochrome b gene in Luanda, Angola
by: Varandas Luís, et al.
Published: (2006-04-01)

Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
by: McKeage, K, et al.
Published: (2003)

Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports.
by: Färnert, A, et al.
Published: (2003)

<it>In vitro </it>atovaquone/proguanil susceptibility and characterization of the <it>cytochrome b </it>gene of <it>Plasmodium falciparum </it>from different endemic regions of Thailand
by: Mungthin Mathirut, et al.
Published: (2008-01-01)

Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.
by: Lacy, MD, et al.
Published: (2002)

Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil.
by: van Vugt, M, et al.
Published: (2002)

The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment
by: Maude, R, et al.
Published: (2014)

The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria.
by: Mcgready, R, et al.
Published: (2003)

Inhibition of the mosquito transmission of Plasmodium berghei by Malarone (atovaquone-proguanil).
by: Butcher, G, et al.
Published: (2000)

Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report.
by: Mcgready, R, et al.
Published: (2003)

Early treatment failure during treatment of <it>Plasmodium falciparum</it> malaria with atovaquone-proguanil in the Republic of Ivory Coast
by: Wurtz Nathalie, et al.
Published: (2012-05-01)

Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed <it>Plasmodium falciparum </it>isolates from Africa
by: Kyle Dennis E, et al.
Published: (2006-10-01)

Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfadoxine for treatment of acute Plasmodium falciparum malaria in Peru
by: A. Llanos-Cuentas, et al.

Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfadoxine for treatment of acute Plasmodium falciparum malaria in Peru
by: Llanos-Cuentas A., et al.
Published: (2001-01-01)

Delayed Onset of Symptoms and Atovaquone-Proguanil Chemoprophylaxis Breakthrough by Plasmodium malariae in the Absence of Mutation at Codon 268 of pmcytb.
by: Beatrix Huei-Yi Teo, et al.
Published: (2015-01-01)

Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia.
by: Ling, J, et al.
Published: (2002)

Absence of an interaction between artesunate and atovaquone--proguanil.
by: van Vugt, M, et al.
Published: (1999)

Malarone treatment failure and <it>in vitro</it> confirmation of resistance of <it>Plasmodium falciparum</it> isolate from Lagos, Nigeria
by: Warhurst David C, et al.
Published: (2002-02-01)

Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis
by: Staines, H, et al.
Published: (2017)

Tolerability of Atovaquone—Proguanil Application in Common Buzzard Nestlings
by: Anja Wiegmann, et al.
Published: (2022-07-01)

Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate.
by: Gupta, R, et al.
Published: (2005)

The mosquito transmission of malaria: the effects of atovaquone-proguanil (Malarone) and chloroquine.
by: Enosse, S, et al.
Published: (2000)

A survey on outcomes of accidental atovaquone–proguanil exposure in pregnancy
by: Kathrine R. Tan, et al.
Published: (2018-05-01)

Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria.
by: Chiodini, P, et al.
Published: (1995)

A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy.
by: Mcgready, R, et al.
Published: (2005)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
by: Ivanovic Jelena, et al.
Published: (2011-05-01)

Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis
by: V Nicosia, et al.
Published: (2008-09-01)

Understanding the mechanism of atovaquone drug resistance in Plasmodium falciparum cytochrome b mutation Y268S using computational methods.
by: Bashir A Akhoon, et al.
Published: (2014-01-01)

Plasmodium vivax and Plasmodium falciparum infection dynamics: re-infections, recrudescences and relapses
by: Michael T. White, et al.
Published: (2018-04-01)

Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (malarone) when taken as chemoprophylaxis
by: Mita, T, et al.
Published: (2003)

Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis.
by: Thapar, M, et al.
Published: (2002)

Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis
by: Mita, T, et al.
Published: (2003)

Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study
by: Naiqi Zhang, et al.
Published: (2022-11-01)

Superior protection in a relapsing Plasmodium cynomolgi rhesus macaque model by a chemoprophylaxis with sporozoite immunization regimen with atovaquone-proguanil followed by primaquine
by: Kosol Yongvanitchit, et al.
Published: (2024-04-01)

A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria.
by: Miriam K Laufer, et al.
Published: (2012-01-01)

Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand.
by: Brockman, A, et al.
Published: (1999)

Sub-microscopic infections and long-term recrudescence of <it>Plasmodium falciparum </it>in Mozambican pregnant women
by: Mandomando Inacio, et al.
Published: (2009-01-01)

HYPOTHESES OF DRUG RESPONSE DYNAMICS TO EXPLAIN RECRUDESCENCE IN ARTESUNATE RESISTANT PLASMODIUM FALCIPARUM MALARIA
by: Maude, R, et al.
Published: (2009)

The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum.
by: Chotivanich, K, et al.
Published: (2012)

The effects of serum lipids on the <it>in vitro</it> activity of lumefantrine and atovaquone against <it>Plasmodium falciparum</it>
by: Chotivanich Kesinee, et al.
Published: (2012-05-01)